How to Get AOD-9604 in the US

The honest short answer

Most “how to get [peptide]” guides walk you through three doors — telehealth, an in-person clinic, or a direct prescription to a compounding pharmacy — and explain how to pick between them. For AOD-9604 in mid-2026, that framing breaks, because all three doors open onto the same wall.

AOD-9604 is not an FDA-approved drug, and — unlike several peptides that are currently between regulatory steps — it has already been formally evaluated for US compounding and was not added to the list that would make it legal to compound. So while a clinician can write the word “AOD-9604” on a prescription, there is no licensed pharmacy that can lawfully turn that prescription into a vial. The route question, for this particular molecule, mostly answers itself: there isn’t a legitimate supply route right now.

That makes this page less a “which door do I choose” comparison and more an honest map of why the doors don’t lead anywhere for AOD-9604 specifically — and what the genuinely legal path looks like if your underlying goal is fat loss rather than this one compound.

Note: This page describes access routes and legal status as of June 2026. The US compounding landscape is in motion and dates matter — always check the current position before acting on anything here.

The three usual routes, and where they lead for AOD-9604

For an FDA-approved medicine, or for a peptide that’s currently compoundable, these three routes are real and distinct. It’s worth walking them so you can see exactly where each one stops for AOD-9604.

Telehealth

A telehealth weight or wellness program connects you with a licensed prescriber by video or questionnaire, and — when the medication is legitimate — ships it from a partner pharmacy. This is the fastest, lowest-friction route for things like approved GLP-1 drugs. For AOD-9604, a telehealth provider can evaluate you, but the partner pharmacy still has nothing lawful to dispense, because the molecule isn’t on the compounding bulks list. A telehealth outfit that does ship you AOD-9604 is either sending a research-only product outside the prescription system or operating in a gray area — neither of which is the clean, regulated route the channel is supposed to provide.

In-person clinic

Regenerative, anti-aging, and hormone clinics are the providers most likely to discuss AOD-9604, because it sits in the GH-adjacent fat-loss niche they market in. An in-person visit gives you a physical evaluation and labs, which is genuinely better oversight than a checkbox form. But the same supply constraint applies on the back end: a clinic can recommend AOD-9604 enthusiastically and still not have a lawful pharmacy channel to fill it. If a clinic is dispensing it anyway, ask where the product is coming from — the answer reveals whether you’re inside the regulated system or outside it.

A direct 503A prescription

The “purest” route — your own prescriber writes a script that a 503A compounding pharmacy fills — is exactly the one that fails most cleanly here. A 503A pharmacy compounding a non-approved drug needs the active ingredient to be an approved-drug component, the subject of an applicable monograph, or on the FDA’s 503A bulk drug substances list. AOD-9604 is none of those. The prescription is writeable; it is not fillable. We unpack that gap in detail on the AOD-9604 prescription page.

Why all three converge

Notice the pattern: every route eventually depends on a pharmacy being able to lawfully produce the thing. The route only changes who evaluates you and how fast — it never changes whether the medicine itself is legal to dispense. For AOD-9604, the legality question is settled at the pharmacy level and the answer is no, so the choice of route is largely cosmetic. This is the opposite of the situation for approved drugs, where the route genuinely matters because the medicine is fillable everywhere.

Why AOD-9604’s door is different from BPC-157’s or TB-500’s

This is the single most important thing to understand, and it’s where a lot of 2026 peptide content gets it wrong by lumping every compound together.

In April 2026 the FDA moved a batch of peptides out of Category 2, and several of those — BPC-157 and TB-500 among them — are scheduled for a fresh advisory committee review in July 2026. Their compounding status is best described as open but unresolved: the formal rulemaking isn’t finished, and whether they ultimately land on the bulks list is still being decided. For those compounds, “the pharmacy may decline to fill” is about availability and caution during an unsettled window.

AOD-9604 is not in that cohort. It was reviewed earlier, in late 2024, and the determination went the other way: it was found not to belong on the 503A bulks list, with the stated concerns including limited long-term human safety data and peptide-impurity issues. It is not on the July 2026 docket. So its door isn’t “open and pending review” — it’s “reviewed and left closed.” That’s a categorically weaker position than BPC-157 or TB-500, and it’s why you can’t simply assume the broader April 2026 loosening swept AOD-9604 along with it. Removal from one list is not the same as addition to the other.

None of this is permanent — a manufacturer could in principle run new trials, or the FDA’s position could be revisited — but as of mid-2026, AOD-9604 the compound has been looked at and is not lawfully compoundable.

The research-only vial lane is not a patient route

The remaining way AOD-9604 physically circulates is through vendors selling it as a “research chemical,” labeled not for human use. It’s worth being blunt: this is not a legal or medical access route, and treating it as one is the exact gray-market scenario these pages exist to steer people away from.

Research-only product carries no prescription, no clinical oversight, and no guarantee of identity, concentration, or purity. The label says “not for human consumption” precisely so the seller sits outside the rules that protect patients. Buying from that lane and self-administering means injecting an unregulated product of unknown content with nobody monitoring you — which is unsafe regardless of how reputable the website looks.

If your goal is fat loss, here’s the route that actually works

Most people asking how to get AOD-9604 don’t have a specific attachment to this exact 16-amino-acid fragment — they want help losing fat, and AOD-9604 surfaced as a peptide that supposedly does that. If that’s you, the honest comparison isn’t between three blocked doors; it’s between a blocked door and an open one.

The open one is the FDA-approved obesity-medication route. Drugs like semaglutide and tirzepatide are prescribable by any qualified provider, fillable at ordinary pharmacies, and supported by large randomized human trials with substantial, well-documented weight loss. You can reach them through the very same telehealth and clinic channels described above — except this time the pharmacy actually has a lawful product to dispense. Our guides to getting semaglutide and choosing a provider walk through that path.

The contrast with AOD-9604 is stark on the evidence too. AOD-9604 was developed in the 1990s in Australia as an “anti-obesity drug,” and it was taken all the way through human obesity trials — an early study showed only a modest edge over placebo, and the larger, longer Phase 2b trial failed to beat placebo on its primary endpoint, after which development was abandoned in 2007. So AOD-9604 isn’t an untested newcomer that might be great; it’s a compound that ran the obesity gauntlet and lost. Chasing a hard-to-obtain, legally closed peptide that already failed, when proven and legally available alternatives exist, is the part most worth pausing on.

The oral-versus-injectable catch

There’s a further wrinkle specific to AOD-9604 that the route discussion usually skips. The form carried through those human trials was an oral preparation. The AOD-9604 sold gray-market today is almost always an injectable. So even setting legality aside, buying it isn’t buying the thing that was studied — it’s buying a different formulation of a compound whose studied version didn’t work. Any claim that injectable gray-market AOD-9604 performs better than the trials is observation and marketing, not trial evidence.

What this means for athletes

If you’re subject to anti-doping testing, the access question is moot in a different way: AOD-9604 appears on the WADA Prohibited List as a growth-hormone fragment, banned at all times. It doesn’t matter whether it came from a clinic, a telehealth program, or a research vial — its presence is a sanctionable finding. Tested athletes should treat AOD-9604 as off-limits outright.

Red flags when someone offers you AOD-9604

Because the legal supply is effectively closed, the way a provider talks about AOD-9604 is itself a useful filter:

• “We can get it for you, no problem.” For a compound that isn’t on the bulks list, easy access means the product is coming from outside the regulated system.
• No evaluation, just purchase. “Buy and inject,” with no labs, history, or follow-up, is the defining warning sign across every gray-market peptide.
• Claims it’s “now legal after the 2026 reclassification.” The April 2026 changes did not put AOD-9604 on the compounding list; a provider implying otherwise is wrong or selling.
• Selling it as the same thing the studies used. It usually isn’t — the studied form was oral, and the trial it’s named after failed.

How to think about it

For AOD-9604 specifically, in mid-2026, the most accurate answer to “how do I get it legally” is: you mostly can’t, because the compound was reviewed for US compounding and not approved for it, leaving the prescription route a dead end and the only remaining supply in the unregulated research lane. The regulatory picture can change, and it’s worth watching the 2026 reclassification if you’re tracking this compound. But if the goal is fat loss rather than this one molecule, the route that actually works — legally, safely, and with real evidence behind it — runs through FDA-approved medicines, not AOD-9604.